Lehman will be asking some hard questions that anybody would ask at this time. Show us where are you going with FISH? Are going for automation or manual protocol? What would be the price for a test? How many patients are flying to China to get HIFU treatment? What is the status of HIFU inventory? Why GE is getting out of CMED? I don't think Lehman cares about CMED's numbers at this time! Needless to say that is already apparent from its low PE and very little interest from institutional side.
Can weather reporters help, I doubt very much. Good day and Good luck!